Followed by increasing accumulation in knowledge of tumor pathogenesis, it is now realized that in addition to chromosome number abnormality, gene translocation and mutation, the important role of epigenetics has become increasingly prominent. Based on the emergence of high-throughput detection methods such as next-generation sequencing technology, the epigenetic (DNA, histone, microRNA, etc.) modification abnormalities in lymphoma can be more comprehensively detected and studied. Those findings show that epigenetic modification has widely affected the pathogenesis, recurrence, progress and drug resistance of lymphoma, which also provide new sights and targets for lymphoma treatment. Based on the relevant abstracts reported on the 61st American Society of Hematology (ASH) Annual Meeting, this article reviews the new progress in epigenetics of lymphoma.